background participants

Participant 034


weakness, dizziness, & paralysis
On this page, you will find information about a UDN participant.

Sharing information on this website is not a requirement of UDN participation. Only descriptions about participants who give explicit consent will appear here. While these participant pages are helpful to understand our participants’ stories, they do not begin to describe their diagnostic odysseys. A special thank you goes out to our participants and their families for sharing their experiences.

 

Female, age 34, with weakness and pain, fatigue, exercise intolerance, and severe episodes of weakness, dizziness, and paralysis.

Date of Report

Mar 30, 2026

Description

The participant is a 34-year-old woman who developed episodic muscle weakness and pain beginning at age 9. Episodes are characterized by acute worsening of weakness, including paralysis, and last from hours to days. Triggers include physical exertion, fasting, illness, stress, and temperature extremes.

Symptoms progressed significantly in early adulthood, leading to severe fatigue, reduced mobility, and loss of function. At peak severity, the participant was unable to sit upright for extended periods, slept most of the day, and required use of a power wheelchair.

The participant’s clinical course demonstrates a pattern consistent with a disorder of energy metabolism. Symptoms worsen with fasting and delayed meals and improve with carbohydrate intake. She experienced meaningful improvement with overnight cornstarch and Glycosade, consistent with benefit from sustained carbohydrate supplementation. Symptoms are also triggered by high-fat intake and alcohol.

In 2023, the participant initiated treatment with high-dose riboflavin (vitamin B2) and coenzyme Q10, resulting in rapid and significant improvement in strength, endurance, and function, including the ability to walk and return to work.

Genetic and metabolic evaluation has identified variants in the ETFDH and ENO3 genes but has not yielded a definitive diagnosis. The overall phenotype (episodic weakness, fasting intolerance, fat intolerance, response to carbohydrate supplementation, and riboflavin responsiveness) is suggestive of an atypical or incompletely characterized disorder of energy metabolism, including a GA2/MADD-like presentation.

Symptoms / Signs

The participant experiences recurrent episodes of acute worsening triggered by physical exertion, fasting or delayed meals, high-fat intake, eating MCT oils (including coconut and palm), alcohol, illness, stress, and temperature extremes. Symptoms during these episodes include:

  • Muscle weakness
  • Paralysis
  • Severe fatigue
  • Muscle pain
  • Sensation of feeling cold with shivering
  • Bradycardia
  • Low oxygen saturation
  • Dark urine

Outside of these episodes, ongoing symptoms include:

  • Muscle weakness
  • Chronic fatigue
  • Exercise intolerance
  • Muscle pain
  • Difficulty walking
  • Gait disturbance (scissor gait and ataxia)
  • Decreased endurance
  • Reduced aerobic capacity
  • Joint hypermobility

The participant has been diagnosed with the following conditions:

  • Postural orthostatic tachycardia syndrome (POTS)
  • Mast cell activation syndrome (MCAS)
  • Asthma
  • Obstructive sleep apnea
  • REM sleep behavior disorder
  • Restless leg syndrome
  • Spinal deformities (lumbar hyperlordosis, scoliosis, L5–S1 spondylolisthesis, and spondylarthritis)
  • Endometrial intraepithelial neoplasia (EIN), status post hysterectomy
  • Cleft lip and palate, status post repair
Current Treatments
  • High-dose riboflavin (vitamin B2) has led to significant improvement in muscle strength, endurance, and fatigue
  • Coenzyme Q10
  • Dietary changes: high-carbohydrate diet with frequent intake and avoidance of high-fat foods, MCT oil, coconut oil, palm oil, alcohol, and fasting
  • Xopenex (levalbuterol) – asthma
  • Duloxetine – chronic pain and POTS
  • Cromolyn sodium – MCAS
  • Cetirizine (Zyrtec) – MCAS
  • Melatonin – REM sleep behavior disorder
  • Iron supplementation – anemia
Prior Treatments
  • Levocarnitine (worsened symptoms)
  • Glycosade (extended-release carbohydrate therapy)
  • Uncooked cornstarch (overnight carbohydrate supplementation)
  • Ketogenic diet (initial symptomatic improvement, but unable to achieve sustained ketosis)
Considered treatments
  • Sodium D,L-3-hydroxybutyrate (NaHB)

Previously Considered Diagnoses
  • Neuromuscular/metabolic myopathy
  • Mitochondrial disorder
  • Multiple acyl CoA dehydrogenase deficiency (MADD)
  • Beta-enolase deficiency (ENO3-related glycolytic myopathy)
  • Pyruvate dehydrogenase deficiency
  • Glucose transporter type 1 deficiency syndrome
  • Organic acid metabolism disorder
  • Pompe disease
  • Hypokalemic periodic paralysis (HypoPP)
  • Channelopathy
  • Multiple sclerosis
  • Rheumatologic disease, including Sjögren’s syndrome
  • Lyme disease
  • Ehlers-Danlos syndrome
  • Rhabdomyolysis
Other Photographs
Genetic Variants of Interest

The following genetic changes are being investigated to see if they are causing the participant’s symptoms:

ETFDH gene – NM_004453.4:c.1151T>C (p.Leu384Pro), variant of uncertain significance (VUS), possibly pathogenic

ETFDH gene – NM_004453.4:c.685-2358C>T (intronic variant), demonstrated not to affect RNA and considered unlikely to be pathogenic

ENO3 gene – variant of uncertain significance (VUS) identified on genomic sequencing; gene associated with glycolytic muscle metabolism

The following genetic changes were identified but are not thought to be causing the participant’s symptoms:

PHYH gene – two variants of uncertain significance (VUSs) identified; biochemical testing (phytanic acid levels) was normal, and these variants are not considered contributory to the participant’s presentation

ADSL gene – heterozygous pathogenic variant consistent with carrier status for adenylosuccinase deficiency; not clinically relevant to the participant’s symptoms

Gene
Inheritance Pattern
Position (hg19)
Transcript
DNA Change
Protein Change
Autosomal recessive
chr4:g.159624609T>C & chr4:g.159614291C>T
NM_004453.4
c.1151T>C & c.685-2358C>T
p.Leu384Pro & N/A
Contact

If this participant sounds like you or someone you know, please contact us!

Disclaimer

The information provided here is based on individual patient experiences. This information is not meant to substitute for advice of a qualified health care provider. Please do not use this information to diagnose or develop a treatment plan for a health problem or disease without consulting a qualified health care provider.

Any mention of products or services is not meant as a recommendation of the products or services. Please discuss any options with a qualified health care provider.

Developments in medical research may impact the information that appears here. No assurance can be given that the information in this site will include the most recent findings or developments.

The use of any information provided on this site is solely at your own risk.

Top